Nexvet Biopharma develops monoclonal antibody therapies for companion animals using its proprietary PETisation™ platform. The platform aims to translate mAbs between species in a single step to create 100% species-specific biologics. Its pipeline includes candidates targeting canine pain, feline pain and canine inflammation. Led by CEO Dr. Mark Heffernan, the company is advancing clinical programs in companion animal health. Nexvet intends to use the Series B proceeds to advance those clinical programs, expand its product pipeline and grow U.S. operations. The company is based in Melbourne, Australia and has previously raised capital, including an AUD$7M round reported in October 2013. Nexvet develops monoclonal antibody therapies for pets, focusing on chronic pain in dogs and cats and atopic dermatitis in dogs. The company uses its PETisation(TM) platform to generate antibodies it says can be safer, less toxic and as effective as small-molecule treatments. Nexvet has demonstrated promising results in recent clinical studies and has more than six antibody programs in development. Leadership includes CEO Dr Mark Heffernan and Vice‑President of Clinical and Regulatory Affairs Dr Colin Giles. The company expects its first product to reach market within 2–3 years and intends to use newly raised funds to continue development and commercialization efforts. Financially, Nexvet has received grants and awards in addition to private capital to support its programs. Nexvet Biopharma is an Australian veterinary medicine developer focused on creating species-equivalent versions of successful human biologics for companion animals such as cats, dogs and horses. Its core technology, PETisation, converts proven human antibody drugs into species-equivalent biologics, allowing the company to leverage a ready supply of validated therapeutic targets. The portfolio targets inflammatory disease, pain and cancer in companion animals. Nexvet is completing a number of further key studies across its pipeline. The company recently signed a licensing deal with a major Japanese animal health company for a canine anti-inflammatory product. The fresh capital will be used to accelerate clinical and business development of its drug portfolio.

Total raised

$41M

Funding rounds

3

Latest round

Series B

Latest activity

Apr 2014